Overview

Branded Generics Market is poised to value over USD 444 million during the forecast period 2020 to 2027.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Branded Generics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Branded Generics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Branded Generics Market:
• Mylan N.V
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Aspen Pharmacare Holding Ltd.
• Abbott Laboratories
• Valeant Pharmaceuticals International, Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Branded Generics Market Segmentation:
By Drug Class 
• Alkylating Agents
• Antimetabolites
• Hormones
• Anti-Hypertensive
• Lipid Lowering Drugs
• Anti-Depressants
• Anti-Psychotics
• Anti-Epileptics
• Others
By Formulation 
• Oral
• Parenteral
• Topical
• Others
By Indication
• Oncology
• Cardiovascular Diseases
• Diabetes
• Neurology
• Gastrointestinal Diseases
• Dermatology Diseases
• Analgesics and Anti-inflammatory
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Drug Stores
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Branded Generics Market By Drug Class, By Formulation, By Indication, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Mode of operation launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1 Objectives of the Study 
   1.2 Market Definition 
   1.3 Market Scope 
       1.3.1 Years Considered for the Study
       1.3.2 Market Covered
   1.4 Currency 
   1.5 Limitations 
   1.6 Stakeholders 

2. Research Applicationology 
    2.1 Research Data 
        2.1.1 Secondary Data
              2.1.1.1 Key Data from Secondary Sources
        2.1.2 Primary Data
              2.1.2.1 Key Data from Primary Sources
    2.2 Market Size Estimation 
    2.3 Market Breakdown and Data Triangulation 
    2.4 Assumptions for the Study  

3. Executive Summary
   3.1 Market Outlook
   3.2 Segment Outlook
   3.3 Competitive Insights

4. Global Branded Generics Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Branded Generics Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Global Branded Generics Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Global Branded Generics Market, By Drug Class Historical Analysis and Forecast 2020-2027 (USD Million)
   7.1. Alkylating Agents
   7.2. Antimetabolites
   7.3. Hormones
   7.4. Anti-Hypertensive
   7.5. Lipid Lowering Drugs
   7.6. Anti-Depressants
   7.7. Anti-Psychotics
   7.8. Anti-Epileptics
   7.9. Others

8. Global Branded Generics Market, By Formulation Historical Analysis and Forecast 2020-2027 (USD Million)  
   8.1. Oral
   8.2. Parenteral
   8.3. Topical
   8.4. Others
  
9. Global Branded Generics Market, By Indication Historical Analysis and Forecast 2020-2027 (USD Million)  
   9.1. Oncology
   9.2. Cardiovascular Diseases
   9.3. Diabetes
   9.4. Neurology
   9.5. Gastrointestinal Diseases
   9.6. Dermatology Diseases
   9.7. Analgesics and Anti-inflammatory
   9.8. Others
   
10. Global Branded Generics Market, By Distribution Channel Historical Analysis and Forecast 2020-2027 (USD Million)  
    10.1. Hospital Pharmacies
    10.2. Retail Pharmacies
    10.3. Online Pharmacies
    10.4. Drug Stores

11. North America Branded Generics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
   11.1. Introduction
   11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
        11.2.1. U.S.A
        11.2.2. Canada
        11.2.3. Mexico
   11.3. Market Size (USD Million) Forecast for North America 2020-2027

12. Latin America Branded Generics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2020-2027

13. Europe Branded Generics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2020-2027

14. Asia Pacific Branded Generics Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027  

15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
          15.2.1. Saudi Arabia
          15.2.2. UAE
          15.2.3. South Africa
          15.2.4. Egypt
    15.3. Market Size (USD Million) Forecast for MEA 2020-2027

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4.  North America - Market Share Analysis and Key Regional Players
    16.5.  Europe - Market Share Analysis and Key Regional Players
    16.6.  Asia Pacific - Market Share Analysis and Key Regional Players
    16.7.  Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Mode of operations Offered and Financial Layouts)
    17.1. Mylan N.V
          17.1.1. Company Overview
          17.1.2. Product Portfolio
          17.1.3. SWOT Analysis
          17.1.4. Financial Overview
          17.1.5. Strategic Overview
    17.2. Novartis AG
          17.2.1. Company Overview
          17.2.2. Product Portfolio
          17.2.3. SWOT Analysis
          17.2.4. Financial Overview
          17.2.5. Strategic Overview 
    17.3. Teva Pharmaceutical Industries Ltd.
          17.3.1. Company Overview
          17.3.2. Product Portfolio
          17.3.3. SWOT Analysis
          17.3.4. Financial Overview
          17.3.5. Strategic Overview
    17.4. Pfizer Inc.
          17.4.1. Company Overview
          17.4.2. Product Portfolio
          17.4.3. SWOT Analysis
          17.4.4. Financial Overview
          17.4.5. Strategic Overview
    17.5. Sun Pharmaceutical Industries Ltd.
          17.5.1. Company Overview
          17.5.2. Product Portfolio
          17.5.3. SWOT Analysis
          17.5.4. Financial Overview
          17.5.5. Strategic Overview          
    17.6. Aspen Pharmacare Holding Ltd.
          17.6.1. Company Overview
          17.6.2. Product Portfolio
          17.6.3. SWOT Analysis
          17.6.4. Financial Overview
          17.6.5. Strategic Overview      
    17.7. Abbott Laboratories
          17.7.1. Company Overview
          17.7.2. Product Portfolio
          17.7.3. SWOT Analysis
          17.7.4. Financial Overview
          17.7.5. Strategic Overview
    17.8. Valeant Pharmaceuticals International, Inc.
          17.8.1. Company Overview
          17.8.2. Product Portfolio
          17.8.3. SWOT Analysis
          17.8.4. Financial Overview
          17.8.5. Strategic Overview 

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures